Citicoline (CDP-choline) in the treatment of Parkinson's disease.

Eberhardt R, Birbamer G, Gerstenbrand F, Rainer E, Traegner H.

Pharmacologic Institute for Clinical Research, 
Munich, Germany.
Clin Ther 1990 Nov-Dec;12(6):489-95

Abstract

Eighty-five patients with an established diagnosis of primary Parkinson's disease were randomly assigned to receive their usual dose of levodopa (mean, 381 mg daily) plus 1,200 mg of CDP-choline daily or half their usual dose of levodopa (mean, 196 mg daily) plus the CDP-choline. Results of the Webster Rating Scale, a pegboard test, drawing, writing, and walking tests, a test of emotional state, and an overall assessment, administered before and after four weeks of treatment, revealed no significant between-group differences. Improvements on the tests were shown by more patients who received half their levodopa dose plus CDP-choline than by those who continued to receive their usual levodopa dose plus the CDP-choline. It is concluded that the levodopa-saving effect of CDP-choline could be used to decrease the incidence of side effects and retard the loss of efficacy of levodopa in long-term treatment.

 | Home | Order |

 1.   CDP choline  may be useful in the treatment of Alzheimer's
 2.   CDP choline  therapeutic effects in Alzheimer's
 3.   CDP choline  choline  effects on cognition in patients with Alzheimer's
 4.   CDP choline  significant improvement in Alzheimer's after 1 month  
 5.   CDP choline  improved mental performance in Alzheimer's
 6.   CDP choline  improvement in glaucoma
 7.   CDP choline  therapeutic value in the treatment of glaucoma
 8.   CDP choline  improved retinal responses in patients with glaucoma
 9.   CDP choline  in acute ischemic stroke
10.  CDP choline  randomized trial in acute ischemic stroke
11.  CDP choline  treatment after traumatic brain injury
12.  CDP choline  action and effects in ischemic brain injury